First Trimester Screening

Testing solutions for expectant mothers

When it comes to risk assessment and diagnosis of prenatal aneuploidy and pre-eclampsia, Revvity Omics offers you a one-stop solution from non-invasive biochemical screening in first trimester to diagnostic testing through cytogenetics, molecular genetics, and genetic counseling. This screening test is generally performed between 11 – 13⁺⁶ weeks of gestation.

Dual marker screening

Analysing biochemical markers along with biophysical markers (Nuchal Translucency, NT or Nasal Bone, NB) in the first trimester of pregnancy using serum or Dried Blood Spot (DBS), Combined / Dual Marker Screening offers high detection rate thus providing early reassurance to you and your patients. The assessment is performed on FMF (UK) approved DELFIA® technology.

Enhanced first trimester screening (eFTS)

Enhanced First Trimester Screening provides screening through four biochemical markers that can be used selectively with different biophysical markers to attain results which enable assessment of the pregnancy and development of appropriate care pathways. It screens for major maternal and fetal problems like fetal aneuploidies, structural defects, and maternal pre-eclampsia. Elevated AFP levels indicate high risks for structural fetal anomalies and placental problems in pregnancy.

Pre-eclampsia screening

Pre-eclampsia screening using PlGF (Placental Growth Factor) allows early identification of a woman at high-risk for pre-eclampsia and increases the likelihood of a better pregnancy outcome. Used in combination with biophysical markers (UTPI and MAP) and established risk factors, it effectively provides the risk interpretation for pre-eclampsia.

Request more information

Full support for early detection

In the first trimester, our assays - PAPP-A, free hCGß, PlGF and AFP - provide effective screening for aneuploidy and other complications of pregnancy. The markers can be used as part of the dual (PAPP-A, free hCGß) or enhanced FTS (PAPP-A, free hCGß, PlGF and AFP) model when ultrasound is available or with enhanced FTS biochemistry-only model.

Our dried blood spot (DBS) assay is optimized for dual marker screening.

Benefits of Revvity Omics’ prenatal screening program

Evidence and guideline-based screening program for risk assessment of Down syndrome and other aneuploidies in first trimester
Follows FMF (UK) guidelines with FMF accredited analyzers for prenatal screening
All maternal markers analyzed – free hCGβ, PAPP-A, PlGF, AFP, uE3, Inhibin-A on Revvity’s AutoDELFIA® platform, are CE-marked.
Graphical interpretation of results with Revvity’s validated LifeCycle® screening management software
Risk interpretation based on MoMs of Indian population developed by screening more than 6 lakh pregnancies over the years

Convenient sampling using Dried Blood Spot (DBS) cards

Our DELFIA®/AutoDELFIA® PAPP-A/Free hCGß Dual DBS (dried blood spot) assay supports easier access to prenatal screening in regions where storage and shipment of serum samples can be a challenge. The sampling process is simple, and the blood spot is obtained by finger-prick.

Simplified sample collection and storage
Improved sample stability
Same detection efficiency as first-trimester serum assay for Down syndrome
No requirement of centrifugation
A practical solution for safe sample transport – No risk of lysis or leakage; minimal risk of contamination or biohazard during sample transport

Reporting: where quality is paramount!

Follows FMF (UK) protocols and guidelines along with stringent regular evaluation by international Quality Assurance Schemes (UK NEQAS, CAP, PMF Taiwan) and stringent audit by NABL and CAP, allowing us to provide quality reports and results – which is also known to be the hallmark to our quality standards. We use the technology and algorithm which are clinically proven and validated by 23 population- based studies, including 2 NIH-sponsored studies examining over 260,000 pregnant women.